Equities Analysts Issue Forecasts for MIRM FY2028 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities researchers at HC Wainwright raised their FY2028 earnings per share estimates for Mirum Pharmaceuticals in a report released on Monday, July 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $3.28 for the year, up from their prior estimate of $2.47. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ FY2029 earnings at $5.79 EPS and FY2030 earnings at $9.81 EPS.

Other analysts have also recently issued research reports about the stock. TD Cowen raised their target price on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Evercore restated an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, June 11th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $143.40.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $112.23 on Wednesday. Mirum Pharmaceuticals has a one year low of $50.25 and a one year high of $130.00. The company has a market cap of $6.84 billion, a PE ratio of -8.25 and a beta of 0.48. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The business has a 50-day simple moving average of $109.47 and a 200-day simple moving average of $101.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The company had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.30) EPS.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total transaction of $611,250.00. Following the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the sale, the senior vice president owned 3,114 shares of the company’s stock, valued at $373,680. This represents a 46.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,315 shares of company stock worth $6,991,928 over the last 90 days. 8.32% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP acquired a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at about $217,000. Finally, Empowered Funds LLC grew its stake in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.